FormulationsFreely Exportable
Artemether + Lumefantrine Tablets
Artemether 20 mg + Lumefantrine 120 mg
WHO-GMP Partner-Manufactured
Target: Africa, SE Asia
Regulatory-Aware Support
Reliable Supply Chain
Product Overview
The leading artemisinin combination therapy (ACT) for uncomplicated malaria, and the mainstay of donor-funded antimalarial procurement across Sub-Saharan Africa. WHO Prequalification support is available through our manufacturing partners for institutional and tender buyers.
Key Points
- WHO-recommended first-line ACT for uncomplicated malaria
- Core Global Fund, PMI and UNICEF procurement line
- WHO-GMP partner-manufactured; WHO PQ status confirmed per manufacturer
Quick Specifications
| Generic Name | Artemether 20 mg + Lumefantrine 120 mg |
|---|---|
| Dosage Form | Tablet |
| Strength | 20 mg / 120 mg |
| HS Code | 3004.60 |
| Packaging | Blister packs (age/weight-banded), institutional bulk packs |
| MOQ | MOQ on request — tender quantities supported |
| Shelf Life | 24–36 months, batch-dependent |
| Storage | Store below 30°C |
Regulatory Information
Schedule H — Prescription Only
Schedule H — B2B and institutional/tender supply. WHO Prequalification status varies by manufacturing partner and is confirmed at quotation stage for donor-funded procurement.
View Antimalarials class detailsRequirements vary by destination. Verify current requirements with the relevant authority before shipment. See our Compliance page.
Request a Quote
Get pricing, MOQ and export details for Artemether + Lumefantrine Tablets.
Need documentation first?
Our team can share a product brochure and manufacturing-partner regulatory summary on request — just mention it in your enquiry.